[STRATEGIC] Biopharma
· Cell Therapy ·
Oncology — February 23, 2026
Gilead Acquires Arcellx for $7.8B, Betting
Everything on Its CAR-T Pipeline for Multiple Myeloma
Gilead's largest deal since 2020: the Foster City biopharma pays
a 79% premium to convert a co-development partnership into full ownership —
capturing 100% of anito-cel's commercial upside and eliminating up to $1.5B in
future milestones.
DEAL SNAPSHOT
|
DEAL VALUE $7.8 Billion |
STRUCTURE Cash Tender Offer + CVR |
|
ANNOUNCED February 23, 2026 |
PRICE PER SHARE $115 cash + $5 CVR (79%
premium) |
|
EXPECTED CLOSE Q2 2026 |
CVR TRIGGER >$6B anito-cel
cumulative sales by 2029 |
THE PARTIES
|
ACQUIRER Gilead Sciences (Nasdaq:
GILD) Foster City,
CA-based biopharma giant with ~$28B in annual revenues. Known for its
transformative HIV franchise (Biktarvy) and cell therapy business Kite
Pharma, acquired for $12B in 2017. Under CEO Daniel O'Day, Gilead has been
aggressive in business development to diversify beyond HIV and build out its
oncology pipeline. Already held ~11.5% of Arcellx prior to this deal. |
TARGET Arcellx Inc. (Nasdaq: ACLX) Redwood City,
CA-based clinical-stage biotech focused on next-generation immunotherapies
for cancer. Lead asset: anitocabtagene autoleucel (anito-cel), a
BCMA-directed CAR T-cell therapy for relapsed/refractory multiple myeloma
being co-developed with Gilead's Kite unit. FDA BLA accepted; PDUFA date
December 23, 2026. |
DEAL OVERVIEW
Gilead will pay
$115 per share in cash — representing a 68% premium to Arcellx's 30-day VWAP as
of February 20, 2026, and approximately 79% to the last close. Additionally,
each share receives one non-transferable contingent value right (CVR) entitling
holders to receive $5 per share if anito-cel achieves cumulative global net
sales of at least $6 billion through year-end 2029.
The structure is
a two-step transaction: Gilead first launches a public tender offer for all
shares it does not already own; upon successful completion (at least a majority
of outstanding shares), it completes the acquisition via a second-step merger.
Both Gilead's and Arcellx's boards have unanimously approved the transaction.
"We are excited to combine Arcellx's innovative CAR-T platform
with Kite's deep cell therapy manufacturing and commercialization
expertise."
— Daniel O'Day,
Chairman & CEO, Gilead Sciences
STRATEGIC RATIONALE
Gilead and
Arcellx have been co-developing anito-cel for multiple myeloma under the Kite
partnership since 2021. By acquiring Arcellx outright, Gilead eliminates the
profit-share arrangement, all remaining milestones (estimated at up to $1.5B),
and future royalties — converting a shared economics model into full ownership
of a potentially blockbuster asset.
BMO analyst Evan
Seigerman estimates the deal saves Gilead up to $1.5 billion in potential
milestone payments alone. Multiple myeloma is one of the most commercially
important blood cancers, with few durable treatment options in the
relapsed/refractory setting. Anito-cel's Phase I/II iMMagine1 data have been
highly competitive, and upon FDA approval (PDUFA December 23, 2026), the
therapy is projected to be EPS-accretive beginning in 2028.
This is Gilead's
largest deal since its $21 billion acquisition of Immunomedics in 2020,
signalling CEO Daniel O'Day's continued commitment to building out Gilead's
oncology platform through selective M&A.
ADVISORS
Buy-side
Financial: BofA Securities Inc. +
Morgan Stanley & Co. LLC
Buy-side
Legal: Ropes & Gray LLP
Sell-side
Financial: Centerview Partners LLC
(exclusive)
Sell-side Legal: Wilson Sonsini Goodrich & Rosati P.C.